Acta Pharmaceutica Sinica B
|
2026, 16(4): 2598-2599
• Correction •
Author correction to “The crucial function of IDO1 in pulmonary fibrosis: from the perspective of mitochondrial fusion in lung fibroblasts and targeted molecular inhibition” [Acta Pharmaceutica Sinica B 15 (2025) 3125-3148]
Full
Lei Wang1, Shanchun Ge1, Ye Zhang1, Deqin Feng2, Ting Zhu3, Louqian Zhang4, Chaofeng Zhang1
Affiliations
1 Sino-Jan Joint Lab of Natural Health Products Research, School of Traditional Chinese Medicines, China Pharmaceutical University, Nanjing 210009, China;
2 State Key Laboratory of Microbial Resources Chinese Academy of Sciences, Beijing 100049, China;
3 Institute of Neuroregeneration & Neurorehabilitation, Department of Pathophysiology, School of Basic Medicine, Qingdao University, Qingdao 266021, China;
4 Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing 210031, China
doi: 10.1016/j.apsb.2026.01.036
Outline
Lei Wang, Shanchun Ge, Ye Zhang, Deqin Feng, Ting Zhu, Louqian Zhang, Chaofeng Zhang.
Author correction to “The crucial function of IDO1 in pulmonary fibrosis: from the perspective of mitochondrial fusion in lung fibroblasts and targeted molecular inhibition” [Acta Pharmaceutica Sinica B 15 (2025) 3125-3148][J].
Acta Pharmaceutica Sinica B,
2026
, 16
(4)
: 2598
-2599
.
DOI: 10.1016/j.apsb.2026.01.036
Year 2026 volume 16 Issue 4
PDF
3
1
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2026.01.036